---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-25-000079"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:25:04.725611+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering

## Summary
- Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.
- Cash and equivalents $10.1M at June 30, 2025; July 2025 offerings added ~$6M net proceeds.
- TakeAim Lymphoma study enrolling PCNSL patients to support US/EU accelerated approval; data expected later 2025.
- Adding proof-of-concept CLL study of emavusertib + BTKi in 20-30 R/R patients; enrollment to begin later 2025.
- TakeAim Leukemia Phase 1/2 enrollment complete; designing registrational trial vs gilteritinib in R/R AML.

## SEC filing metadata
- accession: 0001108205-25-000079
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/0001108205-25-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/cris-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-25-000079
- JSON: https://secwatch.observer/filing/0001108205-25-000079.json
- Plain text: https://secwatch.observer/filing/0001108205-25-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.